Washington, DC – On September 12, the Rare Disease Company Coalition sent a letter to Congressional leadership urging them to support the swift passage of S.4583/H.R. 7384, the Creating Hope Reauthorization Act of 2024.
The bill would reauthorize the rare pediatric disease priority review voucher (PRV) program, a proven policy that has benefitted hundreds of thousands of patients living with a rare disease. Over the past 12 years, the program has been an innovation-driving and cost-effective policy that spurs research & development (R&D) in rare pediatric diseases.
If Congress allows it to expire on September 30, this critical program will be out of reach for many rare disease treatments.
Read the full letter below.